Conmed price target raised to $141 from $131 at KeyBanc

KeyBanc raised the firm’s price target on Conmed to $141 from $131 and keeps an Overweight rating on the shares, citing higher estimates and shift to 2025 valuation. Results and upwardly revised guidance reflected macro strength, as well as core growth drivers, and the firm was encouraged it proactively addressed potential competition for AirSeal.